Pfizer Paxlovid - antiviral pills that still matter in the US COVID toolkit

Pfizer Paxlovid has treated millions of high?risk COVID?19 patients in the US since FDA emergency authorization in December 2021. Anyone holding Pfizer Inc. stock (NYSE: PFE, ISIN US7170811035) should know this product.

By Nora Whitfield, ad hoc news Software & Services Desk. Reviewed July 02, 2026, 7:26 PM ET. Details in the imprint.

Pfizer Paxlovid sits in a white blister pack on the clinic counter, two colors of tablets side by side, waiting for a patient who has just tested positive for COVID?19 and is still scrolling their phone. The prescription oral antiviral remains one of the key tools US doctors use for high?risk adults to cut the odds of severe disease. A nurse I spoke with in Brooklyn described it simply: "It’s the drug we reach for when the test strip turns bright red and the patient has diabetes or heart disease."

What Paxlovid is and how it is used

Paxlovid is Pfizer’s oral antiviral treatment for mild to moderate COVID?19 in patients at high risk of progressing to severe disease, first authorized by the US Food and Drug Administration (FDA) in December 2021 under Emergency Use Authorization (EUA). The regimen combines two medicines: nirmatrelvir, a protease inhibitor that blocks the SARS?CoV?2 3CL protease, and ritonavir, which slows the breakdown of nirmatrelvir in the body to help maintain effective levels. The standard adult course is taken at home: two 150 mg tablets of nirmatrelvir plus one 100 mg tablet of ritonavir, twice daily for five days, with dose adjustments for patients with moderate renal impairment.

The FDA converted Paxlovid from EUA status to full approval in May 2023 for adults at high risk for progression to severe COVID?19, including hospitalization or death. That approval was based on pivotal clinical trial data from the EPIC?HR study, which showed an 89 percent reduction in risk of COVID?19?related hospitalization or death compared with placebo in high?risk, non?hospitalized adults treated within five days of symptom onset. In that randomized, double?blind trial, no deaths were reported in the Paxlovid group compared with multiple in the placebo arm, a result that made the regimen central to the US government’s outpatient COVID response.

US access, pricing and practical realities

In the US, Paxlovid was initially purchased and distributed by the federal government, making the drug available at no direct cost to patients who met eligibility criteria. That changed as the product transitioned to the commercial market, with Pfizer indicating a list price around $1,390 per five?day course in late 2023, though the effective out?of?pocket cost for insured patients is typically lower due to coverage and negotiated discounts. For many Medicare and privately insured patients, co?pays can range from zero to tens of dollars, while uninsured patients face higher costs unless supported by patient assistance programs.

On the ground, clinicians balance that pricing reality with the drug’s risk?benefit profile. Dr. Rochelle Walensky, former director of the US Centers for Disease Control and Prevention (CDC), publicly emphasized Paxlovid’s role for people with risk factors such as older age, obesity or chronic medical conditions, especially when access to monoclonal antibodies declined. The CDC’s current clinical guidance continues to list Paxlovid as a preferred outpatient treatment option, alongside intravenous remdesivir, for eligible patients presenting within five days of symptom onset. A pharmacist in Atlanta described the typical scenario to me: a high?risk patient arrives with a positive test, the prescriber checks a long medication list for potential interactions, then the yellow?and?pink blister pack goes home with three pages of counseling notes.

Drug interactions, rebound and safety profile

Paxlovid’s use is constrained by drug?drug interactions, mainly because ritonavir strongly inhibits CYP3A, a key liver enzyme, which can raise the levels of many commonly used medicines. The product’s FDA label and CDC guidance stress the importance of reviewing medications such as certain antiarrhythmics, statins, immunosuppressants, and psychiatric drugs before prescribing. Some drugs are contraindicated; others require dose adjustments or temporary interruption during the five?day treatment course. This interaction profile has led health systems to issue detailed checklists and electronic decision support tools to help prescribers quickly screen for unsafe combinations.

Safety questions also center on "COVID rebound," a phenomenon where some patients report recurring symptoms and new positive tests after completing Paxlovid. Analyses by the FDA and CDC have indicated that rebound can happen both in treated and untreated patients, and does not appear to be associated with increased rates of hospitalization or death. Pfizer?sponsored data and independent studies suggest that the overall benefit in reducing severe outcomes remains strong, even if a subset of patients experience temporary symptom recurrence. The company updated its labeling to reflect these observations, and infectious disease specialists now typically frame rebound as an annoyance rather than a major safety concern.

Evidence beyond the pivotal trial

Since the EPIC?HR pivotal study, multiple real?world analyses have assessed Paxlovid’s effectiveness across different waves of the pandemic and in vaccinated populations. A large observational study in Israel, for example, reported that Paxlovid was associated with significantly lower hospitalization and death rates among high?risk adults, including many who were previously vaccinated, during an Omicron wave. US health?system data similarly showed continued benefit, though the absolute risk reductions were smaller in some cohorts compared with the early unvaccinated trial population. These evolving data sets have helped public?health officials update their recommendations while COVID variants and population immunity levels continue to shift.

In parallel, researchers have studied potential resistance mechanisms. So far, surveillance has not identified widespread clinically significant resistance to nirmatrelvir, although laboratory work has identified mutations in the viral protease that could reduce drug susceptibility. That dynamic is one reason Pfizer and other companies continue to work on next?generation antivirals. For patients and prescribers, though, the takeaway today is practical: Paxlovid remains one of the few orally administered, at?home treatments with strong evidence for preventing severe COVID in the right risk groups.

Where Paxlovid fits in Pfizer’s business

For Pfizer Inc., Paxlovid joined the mRNA vaccine Comirnaty as a major COVID?related revenue driver in 2022, contributing billions of dollars in global sales. As pandemic demand has eased, the company’s reported Paxlovid revenues have declined, and management has guided investors to expect COVID?related products to represent a smaller portion of total sales over the coming years. Even so, the antiviral continues to matter for Pfizer’s infectious diseases portfolio and for US payers managing COVID risk in vulnerable populations.

Key facts on Pfizer Paxlovid

• Product: Paxlovid (nirmatrelvir/ritonavir)
• Manufacturer: Pfizer Inc.
• Category: Software/Service/Subscription (prescription therapeutic service)
• Launch: FDA EUA granted December 2021; full US approval for high?risk adults in May 2023
• MSRP / Price: Approx. US$1,390 list price per five?day course in the US commercial market; effective patient cost varies by insurance
• Availability: Prescription?only in the US and multiple other markets for high?risk COVID?19 patients meeting clinical criteria
• Target audience: Adults and some pediatric patients at high risk of progression to severe COVID?19, as determined by healthcare providers
• Standout / USP: At?home oral antiviral regimen with strong evidence for reducing hospitalization and death in eligible high?risk COVID?19 patients

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.